Internal Medicine, Infectious Disease · New Orleans, LA
NPI
1235222324
Since 2006
Specialty
Internal Medicine, Infectious Disease
Code 207RI0200X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
1415 Tulane Ave
New Orleans, LA, 70112
Phone (504) 988-5800
Groups this clinician bills Medicare through
Medicare paid, 2024
$15K
180 services
Medicare patients, 2024
89
Average age 69
Drug cost, 2024
$1.7M
1,761 prescriptions
Company payments, 2025
$40.79
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by David M Mushatt was code 99214 (office e&m - established), 59 times for 29 patients. In total David M Mushatt billed 180 services in 14 codes, and Medicare paid $15K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2015-10-22.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 59 | 29 | $71.02 | $4,190 |
| 99232 Hospital E&M - Subsequent | Facility | 34 | 22 | $57.59 | $1,958 |
| 99222 Hospital E&M - Initial | Facility | 25 | 21 | $100.34 | $2,509 |
| 99223 Hospital E&M - Initial | Facility | 22 | 22 | $132.56 | $2,916 |
| 99215 Office E&M - Established | Facility | 20 | 14 | $101.23 | $2,025 |
By year: 2022 $16K for 175 services; 2023 $12K for 132 services; 2024 $15K for 180 services.
Medicare prescription drug claims, 2024
In 2024, the drug David M Mushatt prescribed most often to Medicare patients was Descovy (Emtricitabine/Tenofov Alafenam), with 112 prescriptions and refills. In total David M Mushatt wrote 1,761 Medicare prescriptions that cost $1.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Descovy Emtricitabine/Tenofov Alafenam | 112 | 120 | Under 11 | $257K |
| Isentress Raltegravir Potassium | 98 | 98 | Under 11 | $190K |
| Daptomycin Generic | 69 | 69 | 13 | $88K |
| Ceftriaxone Ceftriaxone Sodium | 56 | 56 | 12 | $6,855 |
| Hydrochlorothiazide Generic | 48 | 62 | Under 11 | $50.99 |
| Ertapenem Ertapenem Sodium | 45 | 45 | Under 11 | $27K |
| Amlodipine Besylate Generic | 44 | 57 | Under 11 | $49.24 |
| Darunavir Generic | 41 | 41 | Under 11 | $38K |
| Ritonavir Generic | 40 | 44 | Under 11 | $15K |
| Meropenem Generic | 38 | 38 | Under 11 | $16K |
| Etravirine Generic | 37 | 37 | Under 11 | $44K |
| Tivicay Dolutegravir Sodium | 37 | 37 | Under 11 | $110K |
| Genvoya Elviteg/Cob/Emtri/Tenof Alafen | 37 | 37 | Under 11 | $149K |
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | 36 | 36 | Under 11 | $154K |
| Tamsulosin Hcl Generic | 28 | 28 | Under 11 | $179 |
Brand drugs: 522 claims; generic drugs: 1,239 claims; opioid claims: 24.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid David M Mushatt $40.79 ($40.79 in general payments such as food, travel and fees) from 1 company. The largest payer was Alexion Pharmaceuticals, Inc. with $40.79.
| Company | Payments | Amount |
|---|---|---|
| Alexion Pharmaceuticals, Inc. AZN | 2 | $40.79 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.